Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.
Br J Clin Pharmacol
; 86(10): 2102, 2020 10.
Article
in En
| MEDLINE
| ID: mdl-32627214
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Br J Clin Pharmacol
Year:
2020
Document type:
Article